Stock Price Movement and Market Context
On 24 Nov 2025, Shree Ganesh Biotech India’s stock price settled at Rs.0.64, representing its lowest level in the past year and also an all-time low. This price is notably below its 52-week high of Rs.1.19, reflecting a substantial contraction in market value over the period. Despite the stock’s decline, the broader market has displayed positive momentum. The Sensex opened 88.12 points higher and was trading at 85,379.45, up 0.17% on the day, and remains within 0.49% of its 52-week high of 85,801.70. The Sensex’s upward trend is supported by its position above the 50-day moving average, which itself is above the 200-day moving average, signalling a bullish market environment.
In contrast, Shree Ganesh Biotech India is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This persistent underperformance relative to technical benchmarks highlights the stock’s current weakness within its sector and the broader market.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Financial Performance and Profitability Indicators
Over the last year, Shree Ganesh Biotech India’s stock has recorded a return of -37.50%, contrasting with the Sensex’s gain of 7.90% over the same period. The company’s financial results for the nine months ending September 2025 reveal a contraction in net sales to Rs.5.16 crores, reflecting a decline of 44.64% compared to the previous period. Correspondingly, the net profit after tax (PAT) stood at a loss of Rs.0.61 crores, also showing a decline of 44.64% year-on-year.
The company’s earnings before interest, taxes, depreciation and amortisation (EBITDA) remain negative, indicating ongoing challenges in generating operating cash flow. The average EBIT to interest ratio is 0.91, suggesting limited capacity to cover interest expenses from operating earnings. Additionally, the average return on equity (ROE) is 2.62%, signalling modest profitability relative to shareholders’ funds.
Another point of concern is the debtors turnover ratio, which for the half-year period is recorded at 0.00 times, indicating potential issues in realising receivables efficiently. These financial metrics collectively point to a fragile fundamental position for the company within the Pharmaceuticals & Biotechnology sector.
Shareholding Pattern and Market Risk
The majority of Shree Ganesh Biotech India’s shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The stock’s valuation appears risky when compared to its historical averages, reflecting the market’s cautious stance on the company’s prospects. Over the past year, profits have declined by approximately 86.6%, underscoring the financial pressures faced by the company.
Considering Shree Ganesh Biotech India ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Sector and Market Comparison
Within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Biotech India’s performance contrasts with the broader market’s positive trajectory. While the Sensex and mega-cap stocks have been leading gains, this micro-cap has not mirrored the sector’s momentum. The stock’s current price level and financial indicators suggest it remains under pressure amid sectoral and market developments.
Summary of Key Metrics
To summarise, the stock’s 52-week low of Rs.0.64 is a reflection of subdued sales, negative profitability, and valuation concerns. The company’s inability to generate positive EBITDA and the low EBIT to interest coverage ratio highlight financial constraints. The return on equity remains modest, and the debtors turnover ratio points to challenges in working capital management. These factors have contributed to the stock’s underperformance relative to the Sensex and sector peers.
Investors observing Shree Ganesh Biotech India will note the divergence between the company’s stock trajectory and the broader market’s gains, underscoring the importance of monitoring fundamental and technical indicators closely.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
